Literature DB >> 23722602

Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression.

Ding-Ping Sun1, Ching-Yih Lin, Yu-Feng Tian, Li-Tzong Chen, Li-Ching Lin, Sung-Wei Lee, Chung-Hsi Hsing, Hao-Hsien Lee, Yow-Ling Shiue, Hsuan-Ying Huang, Chien-Feng Li, Peir-In Liang.   

Abstract

Gallbladder carcinoma (GBC) is a relatively rare disease which pathogenesis is less clarified. Human antigen R (HuR), a RNA-binding protein, modulates the expressions of various cancer-related proteins by stabilizing or regulating the transcription of the corresponding messenger RNA. The significance of HuR expression in a large cohort with GBCs is yet to be evaluated. In total, 164 cases of GBC were selected, and immunostaining for HuR was performed. HuR nuclear (HuR-N) expression and HuR cytoplasmic (HuR-C) expression were evaluated by using a histochemical score. The results of HuR expression were correlated with various clinicopathological factors, disease-specific survival (DSS), and disease-free survival (DFS) in 161 patients with follow-up data. HuR-N overexpression was strongly associated with high histological grade (p = 0.001), vascular invasion (p < 0.001), and high Ki-67 labeling index (p < 0.001). HuR-C overexpression was significantly related to higher primary tumor status (p < 0.001), advanced tumor stage (p < 0.001), histological type (p = 0.006), high histological grade (p < 0.001), vascular and perineurial invasion (p < 0.001 and p = 0.002, respectively), tumor necrosis (p = 0.042), and high Ki-67 labeling index (p = 0.002). Besides, HuR-C overexpression also correlates with HuR-N overexpression (p < 0.001) and cyclin A overexpression (p = 0.026). HuR-N overexpression correlated with poor DFS (p = 0.0348) in univariate analysis, but HuR-C overexpression strongly correlated with a worse DSS and DFS in both univariate (both p < 0.0001) and multivariate (DSS, p = 0.006; DFS, p = 0.001) analyses. Subcellular localization of HuR expression correlates with different adverse phenotypes of GBC. Besides, HuR-C overexpression is an independent prognostic factor for dismal DSS and DFS, suggesting its roles in tumorigenesis or carcinogenesis and as a potential prognostic marker of GBC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23722602     DOI: 10.1007/s13277-013-0872-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  K S McCarty; L S Miller; E B Cox; J Konrath; K S McCarty
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

Review 3.  E- and A-type cyclins as markers for cancer diagnosis and prognosis.

Authors:  Amber Yasmeen; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Expert Rev Mol Diagn       Date:  2003-09       Impact factor: 5.225

4.  Establishment and characterization of a new human gallbladder carcinoma cell line.

Authors:  Shinichi Sekine; Yutaka Shimada; Takuya Nagata; Makoto Moriyama; Testuya Omura; Isaku Yoshioka; Ryouta Hori; Koushi Matsui; Shigeaki Sawada; Tomoyuki Okumura; Toru Yoshida; Kazuhiro Tsukada
Journal:  Anticancer Res       Date:  2012-08       Impact factor: 2.480

5.  Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma.

Authors:  Carsten Denkert; Wilko Weichert; Klaus-Jürgen Winzer; Berit-Maria Müller; Aurelia Noske; Silvia Niesporek; Glen Kristiansen; Hans Guski; Manfred Dietel; Steffen Hauptmann
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

6.  HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer.

Authors:  Xiaofang Yi; Yi Zhou; Wenxin Zheng; Setsuko K Chambers
Journal:  Aust N Z J Obstet Gynaecol       Date:  2009-02       Impact factor: 2.100

7.  Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer.

Authors:  H Puhalla; F Wrba; D Kandioler; M Lehnert; A Huynh; T Gruenberger; D Tamandl; M Filipits
Journal:  Anticancer Res       Date:  2007 May-Jun       Impact factor: 2.480

8.  The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

Authors:  Christina L Costantino; Agnieszka K Witkiewicz; Yuki Kuwano; Joseph A Cozzitorto; Eugene P Kennedy; Abhijit Dasgupta; Judith C Keen; Charles J Yeo; Myriam Gorospe; Jonathan R Brody
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

9.  Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody.

Authors:  D A Budwit-Novotny; K S McCarty; E B Cox; J T Soper; D G Mutch; W T Creasman; J L Flowers; K S McCarty
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

10.  HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma.

Authors:  Peir-In Liang; Wei-Ming Li; Yu-Hui Wang; Ting-Feng Wu; Wen-Ren Wu; Alex C Liao; Kun-Hung Shen; Yu-Ching Wei; Chung-Hsi Hsing; Yow-Ling Shiue; Hsuan-Ying Huang; Han-Ping Hsu; Li-Tzon Chen; Ching-Yih Lin; Chein Tai; Chun-Mao Lin; Chien-Feng Li
Journal:  BMC Cancer       Date:  2012-12-21       Impact factor: 4.430

View more
  10 in total

1.  Krüppel -like factor 8 is a stress-responsive transcription factor that regulates expression of HuR.

Authors:  Suman Govindaraju; Beth S Lee
Journal:  Cell Physiol Biochem       Date:  2014-08-08

Review 2.  Clinical significance of HuR expression in human malignancy.

Authors:  Ioly Kotta-Loizou; Constantinos Giaginis; Stamatios Theocharis
Journal:  Med Oncol       Date:  2014-08-13       Impact factor: 3.064

Review 3.  Adaptive and maladaptive expression of the mRNA regulatory protein HuR.

Authors:  Suman Govindaraju; Beth S Lee
Journal:  World J Biol Chem       Date:  2013-11-26

4.  HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.

Authors:  Aldona Jakstaite; Aurelija Maziukiene; Giedre Silkuniene; Kristina Kmieliute; Antanas Gulbinas; Zilvinas Dambrauskas
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

Review 5.  Post-transcriptional regulation of cytokine and growth factor signaling in cancer.

Authors:  Irina Vlasova-St Louis; Paul R Bohjanen
Journal:  Cytokine Growth Factor Rev       Date:  2016-12-02       Impact factor: 7.638

6.  Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Ioanna Delladetsima; Ioannis Karavokyros; Eugene Danas; Athina Giagini; Efstratios Patsouris; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2016-01       Impact factor: 3.201

7.  BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma.

Authors:  Peir-In Liang; Chien-Feng Li; Li-Tzong Chen; Ding-Ping Sun; Tzu-Ju Chen; Chung-Hsi Hsing; Han-Ping Hsu; Ching-Yih Lin
Journal:  Tumour Biol       Date:  2013-10-11

Review 8.  Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.

Authors:  Aarti Sharma; Kiran Lata Sharma; Annapurna Gupta; Alka Yadav; Ashok Kumar
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

Review 9.  The RNA-Binding Protein HuR in Digestive System Tumors.

Authors:  Xiaoqing Song; Xin Shi; Wenjuan Li; Fa Zhang; Zhonglin Cai
Journal:  Biomed Res Int       Date:  2020-07-24       Impact factor: 3.411

10.  5-FU blocks shuttling of HuR mediated by PKCδ in gastric cancer cells.

Authors:  Wenzhi Wu; Shengnan Xu; Kaiyu Guan; Weiwei Zhang; Congde Chen; Xiaoming Chen; Zipu Hong; Dong Hua
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.